Checkpoint Inhibitor-Induced Pneumonitis in Lung Cancer

<bold>Background</bold> Immune Checkpoint inhibitors (ICI) have revolutionized lung cancer therapy. Immune-related events, such as pneumonitis, are potentially severe adverse events. <bold>Objectives</bold> Assess the incidence, risk factors and outcomes of ICI induced pneumonitis in lung cancer patients. <bold>Methods & results</bold> In this retrospective analysis of 86 lung cancer patients treated between January – July 2023 with ICI, most patients were male (59%), with a median age of 67 years. 60% received pembrolizumab. 5% were never-smokers. 65% had COPD, and 8% had other lung diseases. 6 patients were diagnosed with ICI induced pneumonitis, median onset at 6 months post-initiation of ICI. All cases received adjunctive chemotherapy, and 66% radiotherapy. 5 of the 6 cases were treated with pembrolizumab, and 4 of the 6 had adenocarcinoma. There was no statistically significant difference between patient characteristics in the pneumonitis vs no pneumonitis group. Half of the pneumonitis patients were rechallenged with ICI. 2 continued , 3 discontinued treatment & 1 died <fig><object-id>erj;64/suppl_68/PA5126/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> <bold>Conclusion</bold> No statistically significant differences between patient characteristics who developed ICI pneumonitis was found. This might be due to the small sample size in this retrospective cohort.